ReviewTheranostics2020
Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections.
Review in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Spatial and cellular composition of lung fibrosis induced by multi-walled carbon nanotubes.Journal of nanobiotechnology · 2026Article
- The "cytokine storm" in infection and sepsis: win the battle but lose the war.Military Medical Research · 2026Review
- Therapeutic Opportunities for Macrophage Targeted Nanomedicine in Diabetes Mellitus.International journal of nanomedicine · 2026Review
- Neutrophil-based delivery platforms: from natural mechanisms to engineered therapeutics.Theranostics · 2026Review
- Investigating the relationship between the IL-17 rs2275913, IL-17 rs763780, and the IL-6 rs1800795 genotypes in HIV-positive patients with COVID-19.Molecular biology reports · 2025Article
- Recent advances in the bench-to-bedside translation of cancer nanomedicines.Acta pharmaceutica Sinica. B · 2025Review
- A Cross-talk between Nanomedicines and Cardiac Complications: Comprehensive View.Current pharmaceutical design · 2025Review
- Unveiling the Cutting-Edge Impact of Polarized Macrophage-Derived Extracellular Vesicles and MiRNA Signatures on TGF-β Regulation within Lung Fibroblasts.International journal of molecular sciences · 2024Article
- Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care.Viruses · 2024Review
- Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.Pharmaceutics · 2024Review
- Exploring platelet-derived microvesicles in vascular regeneration: unraveling the intricate mechanisms and molecular mediators.Molecular biology reports · 2024Review
- Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine.Current oncology (Toronto, Ont.) · 2024Review
- Tumor-derived extracellular vesicles regulate macrophage polarization: role and therapeutic perspectives.Frontiers in immunology · 2024Article
- Nanodrug Delivery Systems in Antitumor Immunotherapy.Biomaterials research · 2024Review
- Immunosuppressive dead cell as lung-targeting vehicle and cytokine absorption material for cytokine storm attenuation of pneumonia.Materials today. Bio · 2023Article
- The oral microbiome in autoimmune diseases: friend or foe?Journal of translational medicine · 2023Review
- Nanomedicine approaches to reduce cytokine storms in severe infections.Drug discovery today · 2022Review
- Recent advances in nanomedicines for regulation of macrophages in wound healing.Journal of nanobiotechnology · 2022Review
- Extracellular vesicles derived from macrophages: Current applications and prospects in tumors.Frontiers in bioengineering and biotechnology · 2022Review
- Cryptotanshinone attenuates LPS-induced acute lung injury by regulating metabolic reprogramming of macrophage.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cytokine storms, defined by the dysregulated and excessive production of multiple pro-inflammatory cytokines, are closely associated with the pathology and mortality of several infectious diseases, including coronavirus disease 2019 (COVID-19). Effective therapies are urgently needed to block the development of cytokine storms to improve patient outcomes, but approaches that target individual cytokines may have limited effect due to the number of cytokines involved in this process. Dysfunctional macrophages appear to play an essential role in cytokine storm development, and therapeutic interventions that target these cells may be a more feasible approach than targeting specific cytokines. Nanomedicine-based therapeutics that target macrophages have recently been shown to reduce cytokine production in animal models of diseases that are associated with excessive proinflammatory responses. In this mini-review, we summarize important studies and discuss how macrophage-targeted nanomedicines can be employed to attenuate cytokine storms and their associated pathological effects to improve outcomes in patients with severe infections or other conditions associated with excessive pro-inflammatory responses. We also discuss engineering approaches that can improve nanocarriers targeting efficiency to macrophages, and key issues should be considered before initiating such studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.